{"entity":{"type":"insider","cik":"0002005245","url":"/insider/0002005245","json_url":"/insider/0002005245.json","name":"Siren, L.L.C.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":7,"first":"2024-07-30","last":"2026-02-04","span_basis":"filed_date"},"name_variants":[{"name":"Siren, L.L.C.","source":"filing","n_filings":7,"first_seen":"2024-07-30","last_seen":"2026-02-04"}],"transactions":[{"id":5782187,"accession":"0001193125-26-037644","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-037644","line_url":"/filing/0001193125-26-037644#line-3","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"Artal Group S.A.; Artal International Management S.A.; Artal International S.C.A.; Artal Participations S.a r.l.; DEBBANE RAYMOND; Invus Global Management, LLC; Siren, L.L.C.; Stichting Administratiekantoor Westend; Westend S.A.","owner_display_name":"Artal Group S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1538462.0,"shares_display":"1,538,462","price_per_share":1.3,"price_display":"1.30","price_state":"stated","total_value":2000000.6,"total_display":"2,000,000.60","total_whole":"2,000,001","shares_owned_after":1538462.0,"shares_owned_after_display":"1,538,462","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-04","scope":"insider"},{"id":2181801,"accession":"0000950170-24-135847","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-135847","line_url":"/filing/0000950170-24-135847#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600000.0,"shares_display":"1,600,000","price_per_share":41.65,"price_display":"41.65","price_state":"stated","total_value":66640000.0,"total_display":"66,640,000.00","total_whole":"66,640,000","shares_owned_after":9250005.0,"shares_owned_after_display":"9,250,005","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-12","scope":"insider"},{"id":2958077,"accession":"0000950170-24-131539","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-131539","line_url":"/filing/0000950170-24-131539","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"Scholar Rock Holding Corp","issuer_ticker":"SRRK","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":409433.0,"shares_display":"409,433","price_per_share":38.48648981811432,"price_display":"38.49","price_state":"stated","total_value":15757638.9857,"total_display":"15,757,638.99","total_whole":"15,757,639","shares_owned_after":11051166.0,"shares_owned_after_display":"11,051,166","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-25","filed_date":"2024-11-27","scope":"insider","n_lines":5},{"id":2985829,"accession":"0000950170-24-094800","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-094800","line_url":"/filing/0000950170-24-094800#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":260873.0,"shares_display":"260,873","price_per_share":0.1917,"price_display":"0.19","price_state":"stated","total_value":50009.3541,"total_display":"50,009.35","total_whole":"50,009","shares_owned_after":6317565.0,"shares_owned_after_display":"6,317,565","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-08","filed_date":"2024-08-09","scope":"insider"},{"id":2985822,"accession":"0000950170-24-094800","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-094800","line_url":"/filing/0000950170-24-094800#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61488.0,"shares_display":"61,488","price_per_share":0.1821,"price_display":"0.18","price_state":"stated","total_value":11196.9648,"total_display":"11,196.96","total_whole":"11,197","shares_owned_after":6578438.0,"shares_owned_after_display":"6,578,438","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-07","filed_date":"2024-08-09","scope":"insider"},{"id":2205932,"accession":"0000950170-24-092864","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-092864","line_url":"/filing/0000950170-24-092864#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":55732.0,"shares_display":"55,732","price_per_share":0.1828,"price_display":"0.18","price_state":"stated","total_value":10187.8096,"total_display":"10,187.81","total_whole":"10,188","shares_owned_after":6639926.0,"shares_owned_after_display":"6,639,926","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-06","filed_date":"2024-08-07","scope":"insider"},{"id":2205929,"accession":"0000950170-24-092864","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-092864","line_url":"/filing/0000950170-24-092864#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":164523.0,"shares_display":"164,523","price_per_share":0.1884,"price_display":"0.19","price_state":"stated","total_value":30996.1332,"total_display":"30,996.13","total_whole":"30,996","shares_owned_after":6695658.0,"shares_owned_after_display":"6,695,658","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-05","filed_date":"2024-08-07","scope":"insider"},{"id":2737316,"accession":"0000950170-24-090910","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-090910","line_url":"/filing/0000950170-24-090910#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":286200.0,"shares_display":"286,200","price_per_share":0.2004,"price_display":"0.20","price_state":"stated","total_value":57354.48,"total_display":"57,354.48","total_whole":"57,354","shares_owned_after":6860181.0,"shares_owned_after_display":"6,860,181","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-02","filed_date":"2024-08-05","scope":"insider"},{"id":2737310,"accession":"0000950170-24-090910","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-090910","line_url":"/filing/0000950170-24-090910#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63564.0,"shares_display":"63,564","price_per_share":0.2162,"price_display":"0.22","price_state":"stated","total_value":13742.5368,"total_display":"13,742.54","total_whole":"13,743","shares_owned_after":7146381.0,"shares_owned_after_display":"7,146,381","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-01","filed_date":"2024-08-05","scope":"insider"},{"id":2389003,"accession":"0000950170-24-088020","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-088020","line_url":"/filing/0000950170-24-088020#line-3","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":756835.0,"shares_display":"756,835","price_per_share":0.2209,"price_display":"0.22","price_state":"stated","total_value":167184.8515,"total_display":"167,184.85","total_whole":"167,185","shares_owned_after":7209945.0,"shares_owned_after_display":"7,209,945","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-30","filed_date":"2024-07-30","scope":"insider"},{"id":2388998,"accession":"0000950170-24-088020","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-088020","line_url":"/filing/0000950170-24-088020#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":363949.0,"shares_display":"363,949","price_per_share":0.2353,"price_display":"0.24","price_state":"stated","total_value":85637.1997,"total_display":"85,637.20","total_whole":"85,637","shares_owned_after":7966780.0,"shares_owned_after_display":"7,966,780","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-29","filed_date":"2024-07-30","scope":"insider"},{"id":2388995,"accession":"0000950170-24-088020","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-088020","line_url":"/filing/0000950170-24-088020#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"GLYCOMIMETICS INC","issuer_ticker":"GLYC","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus Global Management, LLC; Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Siren, L.L.C.","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":258335.0,"shares_display":"258,335","price_per_share":0.2417,"price_display":"0.24","price_state":"stated","total_value":62439.5695,"total_display":"62,439.57","total_whole":"62,440","shares_owned_after":8330729.0,"shares_owned_after_display":"8,330,729","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-26","filed_date":"2024-07-30","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001062822","name":"LEXICON PHARMACEUTICALS, INC.","url":"/issuer/0001062822","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-02-04","last_seen":"2026-02-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001727196","name":"Scholar Rock Holding Corp","url":"/issuer/0001727196","role":"Ten percent owner","n_filings":2,"first_seen":"2024-11-27","last_seen":"2024-12-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001253689","name":"GLYCOMIMETICS INC","url":"/issuer/0001253689","role":"Ten percent owner","n_filings":4,"first_seen":"2024-07-30","last_seen":"2024-08-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0002005245","retrieved_at":"2026-08-25T12:34:20+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}